Carboplatin is the most commonly used drug in the first-line treatment of human retinoblastoma (RB), but its clinical application is greatly limited due to acquired drug resistance upon the longterm treatment. Forkhead box protein M1 (FoxM1) is the transcription factor aberrantly expressed in various types of human cancers, which plays an essential role in the regulation of tumorigenesis, tumor metastasis and drug resistance. However, little is known about the role of FoxM1 in chemo-resistance of human RB. In this study, we investigated the regulatory effect of FoxM1 on carboplatin resistance in human RB Y-79 cells and carboplatin-resistant Y-79 (Y-79CR) cells, as well as the possible mechanism. Our results showed that FoxM1 was up-regulated in Y-79CR cells and silencing of FoxM1 promoted carboplatin sensitivity and accumulation, while overexpression of FoxM1 in Y-79 cells performed oppositely. Our study further revealed that FoxM1 enhanced carboplatin resistance in Y-79CR cells through directly up-regulating the transcription of ATP-binding cassette transporter C4 (ABCC4), an important drug efflux transporter. Overall, our study demonstrated the novel role of FoxM1-ABCC4 axis in human RB, which provides insights into the prevention of carboplatin resistance in human RB.
Introduction
Retinoblastoma (RB), with an incidence of~1 in 15,000 new births, is the most common malignant intraocular tumor in children [1] . According to the International Classification of Retinoblastoma, chemotherapy plays an important role in the management of RB with reducing tumor size and suppressing tumor metastasis. One of the most commonly used chemotherapy agents is carboplatin, a platinum-based drug used to treat solid tumors by interfering DNA repair [2] . The widely used systemic chemotherapy of RB includes 6-10 cycles of carboplatin treatment, co-administered with vincristine or etoposide. However, patients with long-term systemic treatment of carboplatin often result in drug resistance. Therefore, searching for new targets so as to improve therapeutic effectiveness and minimize drug resistance is urgent for RB therapy.
Forkhead box protein M1 (FoxM1), also formerly known as HFH-11, MPP-2, WIN or Trident, belongs to the Forkhead transcription factor superfamily. FoxM1 plays an essential regulatory role in a series of biological processes, including cell proliferation, cell cycle progression, cell differentiation, tissue homeostasis and angiogenesis [3] . Previous studies have revealed that FoxM1 is up-regulated in several tumors including RB [4] . FoxM1 was reported to be involved in drug resistance in cancers such as gastric and breast cancers [5, 6] . Zhao et al. reported that FoxM1 overexpression in ovarian cancer resulted in a poor outcome and contributed to paclitaxel resistance by blocking mitotic catastrophe [7] . FoxM1 was also shown to promote drug resistance through upregulating ATP-binding cassette (ABC) transporters [8] ; however, the impact of FoxM1 on chemo-resistance in RB remains unclear.
In this study, we investigated the association of FoxM1 and carboplatin resistance in human RB Y-79 cells as well as in carboplatinresistant Y-79 (Y-79CR) cells.
Materials and Methods

Cell culture
Human retinoblastoma cell line Y-79 and embryonic kidney cell line HEK293T were purchased from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI-1640 medium containing 10% (v/v) heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco, Grand Island, USA) in a humidified atmosphere (95% air, 5% CO 2 ) at 37°C. The carboplatinresistant RB Y-79 (Y-79CR) cells were established by intermittently exposing the RB cells to low concentration of carboplatin.
Quantitative RT-PCR analysis
Total RNA was isolated using Trizol reagent and first-strand cDNA was synthesized using PrimeScript™ RT reagent kit (Takara, Shiga, Japan) according to the manufacturer's protocol. RT-PCR was performed with the cDNA using SYBR ® Premix Ex Taq™ Mix (Takara). The primer pair sequences for amplification were: FoxM1, 5′-TATTCACAGCATCATCACAGC-3′ (forward) and 5′-GAAGG CTCCTCAACCTTAACCT-3′ (reverse); ABCC4, 5′-GGATCCAA GAACTGATGAGTTAAT-3′ (forward) and 5′-TCACAGTGCTGT CTCGAAAATAG-3′ (reverse); β-actin, 5′-GGGACCTGACTGACT ACCTCA-3′ (forward) and 5′-GACTCGTCATACTCCTGCTTG-3′ (reverse). PCR amplification reaction was performed as follows: denaturation at 95°C for 30 s, amplification at 95°C for 5 s (30 cycles), annealing and extension at 60°C for 20 s using ABI7500 sequence detection system (Life Technologies, Carlsbad, USA). The quantity of target genes was normalized to that of β-actin and relative to the control using the comparative ΔΔCt method.
Western blot analysis
Cells were lysed in ice-cold RIPA buffer for 30 min. A total of 50 μg protein of each sample was subject to 15% sodium-dodecyl sulfatepoly-acrylamide gel electrophoresis and transferred to the PVDF membranes. The membranes were blocked with 5% nonfat milk for 1 h at room temperature, and then incubated with the primary antibodies and then with the corresponding HRP-conjugated secondary antibody. Protein bands were visualized using the ECL assay kit (BeyoECL Plus; Beyotime, Nantong, China). The antibodies used were anti-FoxM1 antibody (Santa Cruz Biotech, Santa Cruz, USA), anti-ABCC4 antibody (Santa Cruz Biotech), anti-β-actin antibody (Abcam, Cambridge, USA) and HRP-conjugated goat anti-mouse secondary antibody (Santa Cruz Biotech). 
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Statistical analysis
All data were presented as the mean ± SD for a minimum of three independent experiments in triplicate. All comparisons were made using one-way ANOVA followed by Tukey's post hoc test. SPSS 19.0 software package were used to analyze the data. A value of P < 0.05 was considered as statistically significant. 
Results
FoxM1 is up-regulated in carboplatin-resistant human retinoblastoma Y-79 cells
FoxM1 silencing promotes carboplatin sensitivity in Y-79CR cells
To investigate the effect of FoxM1 silencing on carboplatin sensitivity in Y-79CR cells, FoxM1 knockdown was achieved by transfecting FoxM1 siRNA followed by the assessment of cell viability with carboplatin treatment. As shown in Fig. 2A , siRNA transfection significantly decreased the expression of FoxM1 in Y-79CR cells at both mRNA and protein levels compared with that of control. As shown in Fig. 2B , the results of cell viability assay indicated that FoxM1 silencing significantly increased the sensitivity of Y-79CR cells to carboplatin. In addition, FoxM1 overexpression was achieved by transfecting FoxM1 expression plasmid in Y-79 cells, which significantly decreased the sensitivity of Y-79 cells to carboplatin (Fig. 2C,D) .
FoxM1 silencing enhances carboplatin accumulation in Y-79CR cells
To investigate the effect of FoxM1 silencing on carboplatin accumulation in Y-79CR cells, the intracellular Pt accumulation was assessed. Cells were treated with 100 μM carboplatin for 2 h and cell lysates were collected for intracellular Pt measurement. As shown in Fig. 3 
FoxM1 increases carboplatin resistance in Y-79CR by regulating ABCC4 gene transcription
To investigate the molecular mechanism underpinning the regulatory role of FoxM1 in RB, the involvement of ABC transporter in such process was assessed. As shown in Fig 4A-C 
ABCC4 contributes to FoxM1-induced carboplatin resistance in Y-79CR cells
To investigate the role of ABCC4 in FoxM1-induced carboplatin resistance in Y-79CR cells, ABCC4 knockdown was achieved by ABCC4 siRNA transfection, and then drug sensitivity as well as drug accumulation was assessed. As shown in (Fig. 5C ).
Discussion
Chemo-resistance, either inherent or acquired, is a major constraint of RB treatment. Exploring the mechanisms underlying drug resistance and developing novel therapeutic strategies to overcome such problem are important for RB treatment. In the present study, FoxM1 was shown to be significantly up-regulated in Y-79CR cells, and silencing of FoxM1 increased the sensitivity of Y-79CR cells to carboplatin and drug efflux of carboplatin in Y-79CR cells. Furthermore, FoxM1 directly regulated the transcription of ABCC4, indicated that FoxM1 promoted carboplatin resistance by regulating ABCC4 expression. FoxM1 is a key cell cycle regulator and plays an essential role in maintaining homeostasis between cell proliferation and apoptosis [10] . It is not surprising that an abnormal activation of FoxM1 can lead to severe pathologic conditions including carcinogenesis [11] . Genome-wide expression analysis indicated that in human solid tumors, FoxM1 is one of the most commonly up-regulated genes [12, 13] . Substantial evidence indicates that multiple oncogenic pathways have cross-talked with FoxM1, such as phosphatidylinositol 3-kinase (PI3K)/Akt, nuclear factor-κB, mitogen-activated protein kinase, matrix metalloproteinases and reactive oxygen species [14] . Consistent with its role in tumor initiation and progression, FoxM1 has also been shown to induce the expansion of stem cell compartments and epithelial-mesenchymal-like transition phenotypes [15] [16] [17] . Ultimately, FoxM1 overexpression mediates increased cell proliferation, self-renewal capacity, long-tern viability, cell migration, angiogenesis and drug resistance. FoxM1 confers resistance to chemotherapeutic drugs by equipping cancer cells with protective mechanisms against DNA damage-induced cell death, disrupting mitosis/cytokinesis control and elevating drug efflux [18] . In the present study, the expression of a panel of ABC transporter genes in Y-79CR cells was analyzed and ABCC4 showed concomitant changes along with FoxM1 alteration; and FoxM1 exhibited its transcriptional activity by directly binding to the promoter region of ABCC4.
Before treatment, tumors can be intrinsically resistant to chemotherapy, while some chemo-sensitive tumors acquire chemoresistance after chemotherapy [19] . Tumor cells often obtain strong drug efflux ability, which is a critical mechanism by which they develop chemo-resistance [20] . Increased drug efflux often leads to enhanced drug resistance, which is likely due to up-regulated expression of ABC transporter proteins [21, 22] . A number of evidence has demonstrated that overexpression of cell efflux transporters significantly contributes to drug resistance by constantly pumping out therapeutic drugs [23] . ABC transporters, the largest transporter family constitute a group of transmembrane proteins (seven subclasses designated as ABCA to ABCG), transport metabolites across membranes with ATP consumption [24] . To date, 49 human ABC transporter genes have been characterized in several kinds of cells [24, 25] . In RB patients, several ABC transporter molecules, such as multidrug-resistant protein 1/P-glycoprotein (MDR1/P-gp, ABCB1) and multidrug-resistant-associated protein 1 (MRP1; ABCC1), have been identified and are found to be associated with chemotherapy resistance [26] . Our results showed that activation of the FoxM1-ABCC4 axis resulted in an acceleration of drug efflux in Y-79CR cells; while knockdown of ABCC4 could partially restore the sensitivity of Y-79CR cells to carboplatin.
ABCC4, located on chromosome 13q32.1, is a widely expressed member of multidrug resistance proteins (MRPs) in various tissues. It can transport a broad spectrum of xenobiotics, including antiviral, antibiotic, antihypertensive and anticancer drugs [27] . Current evidence suggests that ABCC4 is implicated not only in cancer biology, but also in chemotherapy resistance. Nalini et al. reported that the expression of ABCC4 in post-chemotherapy RB was significantly up-regulated [28] . Therefore, previous studies and our data demonstrated that chemotherapy-mediated ABCC4 overexpression contributed to the acquired chemo-resistance in RB, and that ABCC4 could be a potential therapeutic target in improving RB treatment.
In conclusion, the present study revealed that the FoxM1-ABCC4 axis plays a critical role in carboplatin-associated drug resistance in human RB and the FoxM1-ABCC4 axis may provide a novel insight into the prevention of carboplatin resistance in human RB therapy.
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